Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | DUT | P33316 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | IGF1R | P08069 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
| ▸ | FLT4 | P35916 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.30 |
| ▸ | TEK | Q02763 | 1/20 | 0.30 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18031341 | 0.81 | NPC1 (0.33) | NPC1DGAT1 | |
| SCHEMBL4611435 | 0.79 | NPC1 (0.33) | NPC1DGAT1 | |
| SCHEMBL25171633 | 0.78 | DGAT1 (0.37) | NPC1DGAT1 | |
| SCHEMBL28496046 | 0.77 | DGAT1 (0.38) | NPC1DGAT1 | |
| SCHEMBL28624418 | 0.76 | DGAT1 (0.37) | NPC1DGAT1F2RL1 | |
| SCHEMBL16611601 | 0.76 | DGAT1 (0.40) | NPC1DGAT1 | |
| SCHEMBL10200583 | 0.76 | DGAT1 (0.34) | NPC1DGAT1 | |
| SCHEMBL30877301 | 0.76 | DGAT1 (0.34) | NPC1DGAT1 | |
| SCHEMBL28912548 | 0.76 | DGAT1 (0.34) | NPC1DGAT1 | |
| SCHEMBL18031342 | 0.76 | NPC1 (0.33) | NPC1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575901-B1 | SUBSTITUTED AMIDES | MERCK SHARP & DOHME (US) | 2012-10-10 | — | — | EP | disclosed |
| US-7816534-B2 | Substituted amides | MERCK SHARP & DOHME CORP. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20090258884-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-7576239-B2 | Substituted amides | MERCK & CO., INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7550489-B2 | Substituted pyridyoxy amides | MERCK & CO., INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20090137529-A1 | SUBSTITUTED ESTERS AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2009-05-28 | — | — | US | disclosed |
| EP-1575901-A4 | SUBSTITUTED AMIDES | MERCK & CO INC (US) | 2009-03-18 | — | — | EP | disclosed |
| EP-2019593-A1 | PRO-DRUGS OF TERTIARY ALCOHOLS | Merck & Co., Inc. (US) | 2009-02-04 | — | — | EP | disclosed |
| US-20080194645-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2008-08-14 | — | — | US | disclosed |
| US-20080171692-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2008-07-17 | — | — | US | disclosed |
| WO-2007136571-A1 | PRO-DRUGS OF TERTIARY ALCOHOLS | MERCK & CO., INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20060106071-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2006-05-18 | — | — | US | disclosed |
| CN-1747926-A | Substituted amide compounds | MERCK & CO INC (US) | 2006-03-15 | — | — | CN | disclosed |
| US-6972295-B2 | Substituted amides | MERCK & CO., INC. (US) | 2005-12-06 | — | — | US | disclosed |
| US-20050234061-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2005-10-20 | — | — | US | disclosed |
| EP-1575901-A2 | SUBSTITUTED AMIDES | Merck & Co., Inc. (a New Jersey corp.) (US) | 2005-09-21 | — | — | EP | disclosed |
| EP-1496838-A2 | SUBSTITUTED AMIDES | Merck & Co., Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| WO-2004058145-A2 | SUBSTITUTED AMIDES | MERCK & CO., INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040058820-A1 | Central nervous system disorders; psychological disorders; antiinflammatory agents; multiple sclerosis | MERCK SHARP & DOHME LLC | 2004-03-25 | — | — | US | disclosed |
| WO-2003077847-A2 | SUBSTITUTED AMIDES | MERCK & CO., INC. (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171692-A1 | Substituted amides | CNR1, CNR2, FAAH | NPC1 337/4885DGAT1 735/4885DUT 4840/4885 |
| US-20060106071-A1 | Substituted amides | CNR1, CNR2, FAAH | NPC1 337/4885DGAT1 735/4885DUT 4840/4885 |
| US-20080194645-A1 | Substituted amides | CNR1, CNR2, FAAH | NPC1 337/4885DGAT1 735/4885DUT 4840/4885 |
| US-20040058820-A1 | Central nervous system disorders; psychological disorders; antiinflammatory agents; multiple sclerosis | CNR1, CNR2, MAG | NPC1 279/4885DGAT1 1323/4885DUT 4869/4885 |
| US-20090137529-A1 | SUBSTITUTED ESTERS AS CANNABINOID-1 RECEPTOR MODULATORS | CNR1, CNR2, CHRNA10 | NPC1 426/4885DGAT1 898/4885DUT 4400/4885 |
| US-20090258884-A1 | Substituted amides | CNR1, CNR2, FAAH | NPC1 337/4885DGAT1 735/4885DUT 4840/4885 |
| US-20050234061-A1 | Substituted amides | CNR1, CNR2, FAAH | NPC1 337/4885DGAT1 735/4885DUT 4840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.